Literature DB >> 1728787

Angioplasty/thrombolytic treatment of failing and failed hemodialysis access sites: comparison with surgical treatment.

D A Kumpe1, M A Cohen.   

Abstract

Angioplasty is a valuable alternative to surgical revision of failing hemodialysis access sites and may be the treatment of choice because no further vein is compromised during the revision and because patency rates with repeat dilatations approach or equal those of surgical revision. Thrombolysis/angioplasty is a worthy substitute for surgical thrombectomy/revision in thrombosed access sites because dialysis can be resumed immediately, without the need of placement of a temporary subclavian vein access catheter, and lysis can be performed on an outpatient basis. Long-term secondary patency also approaches that of surgical therapy. Again, future access sites are not compromised. Either with percutaneous catheter or surgical therapy, it must be recognized that repeat treatment will be necessary to maintain patency of the access site after it has thrombosed. Close follow-up of these patients to observe for signs of recurring deterioration is mandatory. Because the number of vascular access sites is limited, the preservation of each site for as long as possible is important for the long-term management of these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1728787     DOI: 10.1016/0033-0620(92)90021-q

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  2 in total

1.  Demands for vascular access in a renal dialysis unit: implications for a regional vascular unit.

Authors:  E Eguare; S Tierney; R Maher; M Creamer; P Grace; C J Cronin; P Burke
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

2.  Percutaneous treatment of failed native dialysis fistulas: use of pulse-spray pharmacomechanical thrombolysis as the primary mode of therapy.

Authors:  Sung Ki Cho; Heon Han; Sam Soo Kim; Ji Yeon Lee; Sung Wook Shin; Young Soo Do; Kwang Bo Park; Sung Wook Choo; In-Wook Choo
Journal:  Korean J Radiol       Date:  2006 Jul-Sep       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.